MedTrace Logo

Atorvastatin in Management of Newly Diagnosed ITP

NCT03692754 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-09-05

No results posted yet for this study

Summary

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of atorvastatin for the treatment of adults with immune thrombocytopenia (ITP).

Conditions

Interventions

DRUG

Atorvastatin 20mg

Atorvastatin will be given in 20 mg po qn for 1 month

DRUG

Atorvastatin 10mg

Atorvastatin will be given in 10 mg po qn for 1 month

DRUG

Dexamethasone

Dexamethasone will be given in 40mg po qd for 4 days

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Ming Hou, Dr · Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2021-12-01
Completion
2023-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692754 on ClinicalTrials.gov